REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • January 24th, 2024 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Registration Rights Agreement (this “Agreement”) is made and entered into as of January 22, 2024, between Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the several investors signatory hereto (each, an “Investor” and, collectively, the “Investors”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 24th, 2024 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 22, 2024, between Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), and the several purchasers identified on the signature pages hereto (each, including its respective successors and assigns, a “Purchaser”).
FORM OF COMMON STOCK PURCHASE WARRANTOutlook Therapeutics, Inc. • January 24th, 2024 • Biological products, (no disgnostic substances)
This Warrant is one of a series of similar warrants issued pursuant to that certain Securities Purchase Agreement, dated January 22, 2024, by and among the Company and the Purchasers identified therein (the “Purchase Agreement”). All such warrants are referred to herein, collectively, as the “Warrants.”
THIRD AMENDMENT TO CONVERTIBLE PROMISSORY NOTEConvertible Promissory Note • January 24th, 2024 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Third Amendment to Convertible Promissory Note (this “Amendment”) is entered into as of January 22, 2024, by and between Streeterville Capital, LLC, a Utah limited liability company (“Lender”), and Outlook Therapeutics, Inc., a Delaware corporation (“Borrower”). Capitalized terms used in this Amendment without definition shall have the meanings given to them in the Note (as defined below).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 24th, 2024 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of January 22, 2024, between Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), and Syntone Ventures, LLC (including its successors and assigns, the “Purchaser”).
SUPPORT AGREEMENTSupport Agreement • January 24th, 2024 • Outlook Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SUPPORT AGREEMENT (this “Agreement”), dated as of January 22, 2024 is made by and among Outlook Therapeutics, Inc., a Delaware corporation (the “Company”), and the stockholder identified on the signature page hereto (“Stockholder”), a holder of shares of common stock, $.01 par value (the “Shares”) of the Company.
